$ cat ./records/african-union-centre-for-ticks-and-tick-borne-diseases-upgraded-t-2019.txt
African Union Centre for Ticks and Tick-Borne Diseases Upgraded to Produce 2 Million ECF Vaccine Doses
[RECORD.TXT] · cat --full
Through sustained funding via GALVmed — co-funded with the UK's DFID — the Gates Foundation supported infrastructure upgrades at the African Union's Centre for Ticks and Tick-Borne Diseases (CTTBD) in Lilongwe, Malawi, bringing its production capacity to up to 2 million doses of the Muguga cocktail East Coast fever vaccine per 18-month cycle. ILRI separately produced emergency supplies during supply gaps. The CTTBD production program is considered one of the most concrete long-running examples of the Gates Foundation's investment in veterinary vaccine infrastructure targeting a tick-transmitted animal disease.
Source: https://www.cgiar.org/innovations/a-vaccine-against-the-lethal-cattle-disease-east-coast-fever/
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Breakthrough Energy Ventures Invests in Pivot Bio — Nitrogen-Fixing Microbial Coating to Replace Synthetic Fertiliser
Next →
Gates Foundation Invests $55 Million in BioNTech for mRNA HIV and Tuberculosis Vaccines
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.